Nong Yang

7.1k total citations · 2 hit papers
120 papers, 2.2k citations indexed

About

Nong Yang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Nong Yang has authored 120 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Pulmonary and Respiratory Medicine, 89 papers in Oncology and 28 papers in Molecular Biology. Recurrent topics in Nong Yang's work include Lung Cancer Treatments and Mutations (82 papers), Colorectal Cancer Treatments and Studies (33 papers) and Lung Cancer Research Studies (33 papers). Nong Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (82 papers), Colorectal Cancer Treatments and Studies (33 papers) and Lung Cancer Research Studies (33 papers). Nong Yang collaborates with scholars based in China, United States and Japan. Nong Yang's co-authors include Yongchang Zhang, Yunpeng Liu, Tao Jiang, Caicun Zhou, Yan Wang, Qiuxiang Ou, Hua Bao, Xiaoling Tong, Yi Xiang and Xue Wu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Cell.

In The Last Decade

Nong Yang

109 papers receiving 2.2k citations

Hit Papers

Investigating Novel Resistance Mechanisms to Third-Genera... 2018 2026 2020 2023 2018 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
    2018 390 citations Zhe Yang, Nong Yang et al. Clinical Cancer Research profile →
  2. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
    2021 246 citations Shun Lü, Yanping Hu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nong Yang China 23 1.5k 1.5k 642 398 194 120 2.2k
Jean‐François Martini United States 18 1.2k 0.8× 1.1k 0.8× 765 1.2× 447 1.1× 67 0.3× 56 2.0k
Eiji Iwama Japan 21 1.2k 0.8× 1.5k 1.0× 401 0.6× 348 0.9× 78 0.4× 70 1.9k
Yong Wha Moon South Korea 22 685 0.4× 918 0.6× 658 1.0× 335 0.8× 149 0.8× 69 1.8k
Wen Wee United States 27 393 0.3× 1.1k 0.8× 742 1.2× 385 1.0× 246 1.3× 123 2.0k
M. Ratcliffe United Kingdom 20 661 0.4× 680 0.5× 619 1.0× 411 1.0× 126 0.6× 47 1.6k
Richeng Jiang China 19 1.0k 0.7× 600 0.4× 952 1.5× 390 1.0× 69 0.4× 48 1.8k
Marileila Varella‐Garcia United States 13 860 0.6× 623 0.4× 618 1.0× 277 0.7× 80 0.4× 16 1.4k
Christopher T. Gubish United States 13 683 0.4× 858 0.6× 723 1.1× 189 0.5× 92 0.5× 17 1.6k
Mirko Marabese Italy 23 638 0.4× 822 0.6× 913 1.4× 369 0.9× 93 0.5× 54 1.6k

Countries citing papers authored by Nong Yang

Since Specialization
Citations

This map shows the geographic impact of Nong Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nong Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nong Yang more than expected).

Fields of papers citing papers by Nong Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nong Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nong Yang. The network helps show where Nong Yang may publish in the future.

Co-authorship network of co-authors of Nong Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Nong Yang. A scholar is included among the top collaborators of Nong Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nong Yang. Nong Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Huajun, Hai‐Yan Tu, Yanping Hu, et al.. (2025). A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001). Journal of Hematology & Oncology. 18(1). 3–3. 3 indexed citations
2.
Ohe, Yuichiro, Satoshi Watanabe, Xiubao Ren, et al.. (2024). BEAT-SC: A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).. Journal of Clinical Oncology. 42(16_suppl). 8001–8001. 15 indexed citations
3.
Li, Ziming, Zhengbo Song, Nong Yang, et al.. (2024). SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study. Signal Transduction and Targeted Therapy. 9(1). 182–182. 13 indexed citations
4.
5.
Yang, Yunpeng, Jie Min, Nong Yang, et al.. (2023). Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial. Signal Transduction and Targeted Therapy. 8(1). 301–301. 15 indexed citations
6.
Jiang, Wenjuan, Zhan Wang, Deng Li, et al.. (2023). Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics. Expert Review of Respiratory Medicine. 17(9). 743–751. 2 indexed citations
7.
Huang, Yan, Qitao Yu, Nong Yang, et al.. (2023). Tislelizumab plus chemotherapy in patients with advanced brain metastases of non-squamous non-small cell lung cancer: A multicenter, prospective, open-label phase 2 study.. Journal of Clinical Oncology. 41(16_suppl). 9080–9080. 2 indexed citations
8.
9.
Yang, Nong, Yongchang Zhang, Liang Zeng, et al.. (2023). The combination therapy of anlotinib and penpulimab for the treatment of small cell lung cancer after platinum-based chemotherapy: Results of a phase II exploratory study.. Journal of Clinical Oncology. 41(16_suppl). e20628–e20628.
10.
Yang, Nong, Juan Chen, Qian Chu, et al.. (2023). Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB–III non‐small cell lung cancer patients using radiomic features. Thoracic Cancer. 14(28). 2869–2876. 7 indexed citations
11.
Zhang, Yongchang, Rui Han, Yubo Wang, et al.. (2022). The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer. Cancer Medicine. 12(5). 5603–5614. 4 indexed citations
12.
Jiang, Wenjuan, Yuling Zhou, Liang Zeng, et al.. (2022). The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study. Translational Lung Cancer Research. 11(4). 647–655. 4 indexed citations
13.
Zhang, Yongchang, Zhe Huang, Liang Zeng, et al.. (2022). Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements. npj Precision Oncology. 6(1). 20–20. 11 indexed citations
14.
Zhou, Qing, Chong‐Rui Xu, Ying Cheng, et al.. (2021). Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 39(9). 1279–1291.e3. 144 indexed citations
15.
Zhang, Yongchang, Liang Zeng, Chunhua Zhou, et al.. (2020). Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. Journal of Thoracic Oncology. 15(6). 1027–1036. 42 indexed citations
16.
Zhang, Yisheng, et al.. (2019). P2.14-51 Dual ALK Fusion Partners as Poor Predictive Marker in First Line Crizotinib Treated ALK Rearranged Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S849–S850. 2 indexed citations
17.
Yang, Zhe, Nong Yang, Qiuxiang Ou, et al.. (2018). Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients. Clinical Cancer Research. 24(13). 3097–3107. 390 indexed citations breakdown →
18.
19.
Zhang, Y., et al.. (2018). P116 Real World Data of 1st Line A+T in Advanced EGFR+ NSCLC: Clinical Outcome, PFS Influential Factors and Acquired Resistance. Journal of Thoracic Oncology. 13(12). S1090–S1090. 1 indexed citations
20.
Yang, Nong, Weiwei Ma, Yueqin Li, et al.. (2014). Prospective Clinical Application of Thioredoxin Reductase as a Novel Diagnostic Tumor Marker. Journal of Biosciences and Medicines. 2(4). 44–53. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean‐François Martini Breakdown of academic impact, for papers by Eiji Iwama Breakdown of academic impact, for papers by Yong Wha Moon Breakdown of academic impact, for papers by Wen Wee Breakdown of academic impact, for papers by M. Ratcliffe Breakdown of academic impact, for papers by Richeng Jiang Breakdown of academic impact, for papers by Marileila Varella‐Garcia Breakdown of academic impact, for papers by Christopher T. Gubish Breakdown of academic impact, for papers by Mirko Marabese
Rankless by CCL
2026